Ananda Developments PLC (AQSE:ANA) has unveiled further promising results for MRX1 in treating heart failure.
Specifically, the findings strengthen the potential of the CBD treatment as a therapy for heart failure with preserved ejection fraction (HFpEF), a condition where the heart struggles to relax despite normal pumping function.
The latest research showed a significant reduction in NT-proBNP levels, a biomarker used to diagnose and manage heart failure.
Lower NT-proBNP levels indicate reduced cardiac stress and improved heart function.
MRX1 also demonstrated improvements in markers associated with fibrosis, oxidative damage, and cardiac stress, which suggest broader protective effects for the heart.
These results build on earlier findings released in June, where MRX1 showed potential to enhance heart and lung health while reducing tissue damage in preclinical models.
The data will also support the company’s patent application for MRX1 and guide future human clinical trials.
HFpEF is a challenging form of heart failure, often characterised by symptoms such as breathlessness and fatigue.
Effective treatment options remain limited, making these developments particularly noteworthy.
Melissa Sturgess, Ananda's CEO, said: "We are delighted to share these new findings. The demonstration by MRX1 that it significantly reduced NT-proBNP, a marker of heart failure, in mice provides compelling evidence of MRX1's potential to address the underlying mechanisms of heart failure.
"As NT-proBNP is a key biomarker recommended by NICE, it will also serve as a critical measure of efficacy in any future human trials we can commission. Ananda is committed to advancing this research into transformative therapies for patients worldwide."
MRX1 is currently being developed to treat pain and inflammation.
To learn more, click here.